Avastin - About Lung Cancer

ZURICH (Reuters) - Roche's top-selling Avastin helps patients with the most common form of lung cancer live longer than any other treatment, the Swiss drugmaker said on Friday, giving the drug a boost after a slew of setbacks.A late-stage trial showed first-line ...

Study is Second Positive Phase III Trial of Tarceva as First-Line Maintenance Therapy --. DNA) today announced that a Phase III study (ATLAS) of Tarceva? (erlotinib) in combination with Avastin? (bevacizumab) as maintenance therapy following initial treatment with Avastin plus chemotherapy in ...

Phase III trial shows patients with advanced adenocarcinoma of the lung have a 45% better chance of survival with Avastin. BASEL, Switzerland, 13 November 2008--Roche announced today that an exploratory analysis of the pivotal phase III E4599 study demonstrated that Avastin (bevacizumab) ...

OSIP) today announced that a randomized Phase III study (BeTa Lung) evaluating Avastin? (bevacizumab) in combination with Tarceva? (erlotinib) in patients with advanced non-small cell lung cancer (NSCLC) whose disease had progressed following platinum-based chemotherapy did not meet its primary endpoint of ...

BASEL, Switzerland, 15 September 2008 - The final analysis of the Avastin in lung study (AVAiL) in patients with advanced lung cancer has shown that not only did the drug significantly slow down the disease progression, it also enabled some patients to ...

DNA) today announced an update for the previously reported Roche-sponsored international Phase III clinical study (AVAiL) of Avastin(R) (bevacizumab) in combination with gemcitabine and cisplatin chemotherapy, in patients with advanced, non-squamous, non-small cell lung cancer (NSCLC). The update confirmed the clinically and ...

Roche Holding AG said Friday that its cancer drug Avastin has been approved in Europe for the treatment of patients with some forms of lung cancer.The drug has been approved to treat advanced non-small cell lung cancer, the most common form of ...

Topic: Avastin

Roche's Avastin gives best lung cancer survival rate

Phase III Study Showed Tarceva in Combination With Avastin as First-Line Maintenance Therapy Improved Progression-Free Survival in Advanced Lung Cancer

Avastin Gives an Additional Four Months of Life to Patients with One of the Most Common Types of Lung Cancer

Genentech and OSI Pharmaceuticals Announce Topline Results from Phase III Study Evaluating the Combination of Avastin and Tarceva as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer

AVAiL study shows longest survival in patients with advanced non-small cell lung cancer

Genentech Provides Update on ''AVAiL'' Phase III Study of Avastin Plus Chemotherapy in First-Line, Advanced, Non-Squamous, Non-Small Cell Lung Cancer

Roche wins European approval for lung cancer drug

From Around the Web

Video Gallery

Follow this Topic with...